Researchers have discovered a link between hyperactivation of the cyclin-dependent kinase CDK protein and mutant KRAS (a protooncogene) addiction. They have used this link to treat mutant KRAS-dependent pancreatic cancer, which is very aggressive and resistant to conventional therapy, and found it to be highly effective. According to a preclinical study published in Clinical Cancer Research , researchers have identified a novel drug that is effective against the malignant spread of pancreatic tumors associated with KRAS gene mutation. According to National Cancer Institute, pancreatic cancer accounts for 3% of all new cancer cases and 8% of all cancer-related deaths.
Pancreatic cancer has a low survival rate as it is quite difficult to detect early. Among all pancreatic cancers, 90% of them are associated with KRAS mutation. However, it is unknown as to what drives KRAS dependency. To…
